ONCAlert | Upfront Therapy for mRCC
Latest From Society of Hematologic Oncology
Targeted Oncology Welcomes the Society of Hematologic Oncology to Its Strategic Alliance Partnership Program
2:30 PM, Wed January 8, 2020
Relapsed/Refractory MCL Landscape Continues to Evolve
7:50 PM, Sat September 15, 2018
Heterogeneous Features Found in Analysis of Triple-Negative Myelofibrosis
7:09 PM, Sat September 15, 2018
When to Consider the "Watch and Wait" Approach in MCL
10:14 PM, Fri September 14, 2018
Investigators Working to Improve Cure Rate in DLBCL
7:47 PM, Fri September 14, 2018
Safety of Carfilzomib Combinations Confirmed in Multiple Myeloma
6:35 PM, Fri September 14, 2018
Venetoclax/Navitoclax Combo Demonstrates Promising Efficacy in Relapsed/Refractory ALL, Lymphoblastic Lymphoma
11:40 PM, Thu September 13, 2018
Beyond Therapeutic Advances, Elimination of MRD and Less Toxic Regimens Needed in AYA Patients With ALL
11:52 PM, Wed September 12, 2018
Resistance to Hydroxyurea Spurs Investigators to Seek Further Treatments in PV
9:02 PM, Wed September 12, 2018
Ruxolitinib May Prove Beneficial in Combination for Myelofibrosis
8:40 PM, Wed September 12, 2018